A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)

Organon

Status and phase: Completed; Phase 3

Conditions: Osteoarthritis

Treatments: Drug: MK0663, etoricoxib; Drug: Comparator: celecoxib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00092768

0663-076

2004_057

Details and patient eligibility

About

The purpose of this study is to compare the safety and effectiveness of an investigational drug and an approved drug in the treatment of osteoarthritis of the knee and hip.

Full description

The duration of treatment is 26 weeks.

Enrollment: 500 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Osteoarthritis of the knee or hip which requires treatment with a medication to obtain pain relief

Exclusion criteria

• Any known allergy to the study drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind